# IBTROZI

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ibtrozi
Canonical HTML page: https://getbiobrief.com/entity/ibtrozi

## Timeline

- **2026-09-06**: Coverage Highlights Market Divergence — Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
- **2026-09-03**: Cramer Calls NUVB 'Pure Speculation' — On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
- **2026-08**: FDA Grants Fast Track Designation to Safusidenib — Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.

## Recent coverage (1 stories)

### Nuvation Bio's 1 Approved Drug vs Cramer's 5-Word 'Pure Spec' Call
2026-09-07 19:39:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Nuvation Bio's experimental brain cancer drug safusidenib won FDA Fast Track in August 2026, but Jim Cramer on CNBC called the surging stock pure speculation. While IBTROZI showed commercial traction as the most-prescribed new lung cancer treatment in early 2026, most value still hinges on late-stage pipeline data.
Full story: https://getbiobrief.com/story/nuvation-bio-cramer-pure-spec-fast-track-safusidenib

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.